PASG News and Press, Passage Bio Inc.

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: O...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.0% to $2.64 on volume of 338,313,823 shares Datavault AI Inc. (DVLT) rose 42.6% to $1.44 on volume of 298,063,233 shares Oriental Culture Holding LTD (OCG) fell 63.3% to $0.0378 ...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.2% to $2.635 on volume of 313,129,849 shares Datavault AI Inc. (DVLT) rose 41.1% to $1.4255 on volume of 273,382,842 shares Hyperscale Data Inc. (GPUS) fell 6.7% to $0.2547 on vo...

2025-11-10 17:00:12 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seeking Alpha For further details see: Passage Bi...

Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high-productivity, suspension-based PBFT02 manufacturing process O...

PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in...

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in...

PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C. Wainwright 27th Annual Global Inves...

Passage Bio Inc. (PASG) is expected to report $-4 for Q2 2025

2025-08-12 07:39:18 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seeking Alpha For further details see: Passage Bi...